Emergent BioSolutions
EBS
$3.27
Share price
3.15%
Change (1 day)
-89.36%
Change (1 year)
Categories
Emergent BioSolutions (EBS) - Cash on Hand
Cash on Hand as of June 2023 : $88.6 M
According to Emergent BioSolutions
's latest financial reports the company has $88.6 M in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Emergent BioSolutions - Cash on Hand chart (from 2004 to 2023)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2022-12-31 | $0.64 B | 11.54% |
| 2021-12-31 | $0.57 B | -7.28% |
| 2020-12-31 | $0.62 B | 270.26% |
| 2019-12-31 | $0.16 B | 49.55% |
| 2018-12-31 | $0.11 B | -37.07% |
| 2017-12-31 | $0.17 B | -34.33% |
| 2016-12-31 | $0.27 B | -13.2% |
| 2015-12-31 | $0.31 B | 11.51% |
| 2014-12-31 | $0.28 B | 56.41% |
| 2013-12-31 | $0.17 B | 26.59% |
| 2012-12-31 | $0.14 B | -2.88% |
| 2011-12-31 | $0.14 B | -14.72% |
| 2010-12-31 | $0.17 B | 66.19% |
| 2009-12-31 | $0.10 B | 12.52% |
| 2008-12-31 | $91.47 M | -13.48% |
| 2007-12-31 | $0.10 B | 38.36% |
| 2006-12-31 | $76.41 M | 110.55% |
| 2005-12-31 | $36.29 M | 432.09% |
| 2004-12-31 | $6.82 M | |
| 2002-12-31 | $4.89 M | -16.45% |
| 2001-12-31 | $5.85 M |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $19.97 B | 22,441.76% | 🇺🇸 USA |
 Merck MRK | $10.38 B | 11,623.48% | 🇺🇸 USA |
 GlaxoSmithKline GSK | $8.20 B | 9,160.23% | 🇬🇧 UK |
 Soligenix SNGX | $10.26 M | -88.41% | 🇺🇸 USA |
 SIGA Technologies SIGA | $76.21 M | -13.98% | 🇺🇸 USA |
 Celldex Therapeutics CLDX | $0.25 B | 185.21% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | $2.66 B | 2,912.42% | 🇮🇱 Israel |